InteKrin Therapeutics Obtains $18,250,000 Series C Round

  • Feed Type
  • Date
    8/4/2008
  • Company Name
    InteKrin Therapeutics
  • Mailing Address
    4300 El Camino Real Los Altos, CA 94022
  • Company Description
    InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity.
  • Website
    http://www.intekrin.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $18,250,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Amgen Ventures
  • Venture Investor
    Skyline Ventures
  • Venture Investor
    Sofinnova Ventures
  • Venture Investor
    OrbiMed
  • Venture Investor
    Sears Capital Management Inc.
  • Venture Investor
    Vivo Ventures
  • Venture Investor
    Asset Management Company

Trending on Xconomy